Browsing by Author "Spelman, Tim"
Now showing items 1-12 of 12
-
Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS
Lorscheider, Johannes; Jokubaitis, Vilija G.; Spelman, Tim; Izquierdo, Guillermo; Lugaresi, Alessandra; Havrdova, Eva; Granella, Franco (Lippincott Williams & Wilkins, 2017)Objective: To investigate the effect of disease-modifying treatment on short-term disability outcomes in secondary progressive multiple sclerosis (SPMS). Methods: Using MSBase, an international cohort study, we previously ... -
Cladribine versus fingolimod, natalizumab and interferon for multiple sclerosis
Kalincik, Tomas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Havrdova, Eva; Trojano, Maria; Barnett, Michael (Sage Publications Ltd, 2018)Objective: This propensity score-matched analysis from MSBase compared the effectiveness of cladribine with interferon , fingolimod or natalizumab. Methods: We identified all patients with relapse-onset multiple sclerosis, ... -
Comparative efficacy of first-line natalizumab vs IFN-beta or glatiramer acetate in relapsing MS
Spelman, Tim; Kalincik, Tomas; Jokubaitis, Vilija; Zhang, Annie; Pellegrini, Fabio; Wiendl, Heinz; Lechner-Scott, Jeannette (Lippincott Williams & Wilkins, 2016)Background: We compared efficacy and treatment persistence in treatment-naive patients with relapsing-remitting multiple sclerosis (RRMS) initiating natalizumab compared with interferon-beta (IFN-beta)/glatiramer acetate ... -
Comparison of Switch to Fingolimod or Interferon Beta/Glatiramer Acetate in Active Multiple Sclerosis
He, Anna; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Trojano, Maria; Luis Sanchez-Menoyo, Jose (Amer Medical Assoc, 2015)IMPORTANCE After multiple sclerosis (MS) relapse while a patient is receiving an injectable disease-modifying drug, many physicians advocate therapy switch, but the relative effectiveness of different switch decisions is ... -
Defining reliable disability outcomes in multiple sclerosis
Kalincik, Tomas; Cutter, Gary; Spelman, Tim; Jokubaitis, Vilija; Havrdova, Eva; Horakova, Dana; Ramo, Cristina (Oxford Univ Press, 2015)Prevention of irreversible disability is currently the most important goal of disease modifying therapy for multiple sclerosis. The disability outcomes used in most clinical trials rely on progression of Expanded Disability ... -
The effect of oral immunomodulatory therapy on treatment uptake and persistence in multiple sclerosis
Warrender-Sparkes, Matthew; Spelman, Tim; Izquierdo, Guillermo; Trojano, Maria; Lugaresi, Alessandra; Grand'Maison, Francois; Van Pesch, Vincent (Sage Publications Ltd, 2016)Objective: We aimed to analyse the effect of the introduction of fingolimod, the first oral disease-modifying therapy, on treatment utilisation and persistence in an international cohort of patients with multiple sclerosis ... -
Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod
Fragoso, Yara Dadalti; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Vucic, Steve; Haartsen, Jodi (Elsevier Sci Ltd, 2018)Background: Fingolimod is an efficient and safe drug for treating relapsing-remitting multiple sclerosis (RRMS). In vivo, fingolimod is phosphorylated and binds to "sphingosine-1-phosphate"(S1P) receptors that are expressed ... -
Predictors of relapse and disability progression in MS patients who discontinue disease-modifying therapy
Kister, Ilya; Spelman, Tim; Patti, Francesco; Duquette, Pierre; Trojano, Maria; Izquierdo, Guillermo; Butzkueven, Helmut (Elsevier Science Bv, 2018)Background: Discontinuation of disease-modifying therapies (DMTs) for MS is common. MSBase, a large global observational registry, affords a unique opportunity to investigate predictors of 'post-DMT' relapses and confirmed ... -
Quantifying risk of early relapse in patients with first demyelinating events: Prediction in clinical practice
Spelman, Tim; Meyniel, Claire; Ignacio Rojas, Juan; Lugaresi, Alessandra; Izquierdo, Guillermo; Grand'Maison, Francois; Kalincik, Tomas (Sage Publications Ltd, 2017)Background: Characteristics at clinically isolated syndrome (CIS) examination assist in identification of patient at highest risk of early second attack and could benefit the most from early disease-modifying drugs (DMDs). ... -
Reply to: Comment on YD Fragoso et al.: "Lymphocyte count in peripheral blood is not associated with the level of clinical response to treatment with fingolimod" [Mult. Scler. Relat. Disord. (2017)]
Fragoso, Yara Dadalti; Brooks, Joseph Bruno B.; Spelman, Tim; Boz, Cavit; Alroughani, Raed; Lugaresi, Alessandra; Haartsen, Jodi (Elsevier Sci Ltd, 2018)… -
Switch to Natalizumab versus Fingolimod in Active Relapsing-Remitting Multiple Sclerosis
Kalincik, Tomas; Horakova, Dana; Spelman, Tim; Jokubaitis, Vilija; Trojano, Maria; Lugaresi, Alessandra; Bergamaschi, Roberto (Wiley, 2015)ObjectiveIn patients suffering multiple sclerosis activity despite treatment with interferon or glatiramer acetate, clinicians often switch therapy to either natalizumab or fingolimod. However, no studies have directly ... -
Towards personalized therapy for multiple sclerosis: prediction of individual treatment response
Kalincik, Tomas; Manouchehrinia, Ali; Sobisek, Lukas; Jokubaitis, Vilija; Spelman, Tim; Horakova, Dana; Iuliano, Gerardo (Oxford Univ Press, 2017)Timely initiation of effective therapy is crucial for preventing disability in multiple sclerosis; however, treatment response varies greatly among patients. Comprehensive predictive models of individual treatment response ...
